Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Can Fite Biopharma ADR Representing 300 Ord Shs CANF

Healthcare Biotechnology
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.


NYSEAM:CANF - Post by User

Can Fite Biopharma ADR Representing 300 Ord Shs
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(267)
•••
Post by whytestockson Jun 05, 2024 7:15pm
53 Views
Post# 36074191

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase
NEWS: $CANF Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 StudyNamodenoson granted Orphan Drug and Fast track status from the FDA Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced an update on...CANF - Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities